Test Price
2,800 AEDโ Home Collection Available
ACTG1 Gene Autosomal Dominant Deafness Type 20 (DFNA20) Genetic Test in UAE | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM)
Clinical Guidance: Complimentary Telephonic Post-Test Interpretation by Senior Genetic Counsellor
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
The ACTG1 NGS test analyses the entire coding region of the gamma-actin gene to detect pathogenic variants causing autosomal dominant nonsyndromic sensorineural hearing loss (DFNA20/26). This molecular diagnostic assay provides definitive genetic confirmation essential for personalised audiological management and family counselling in the UAE.
Test Overview & Methodology
The ACTG1 genetic test utilises Next Generation Sequencing (NGS) to interrogate the entire coding region and splice junctions of the gamma-actin gene. This assay detects single nucleotide variants, small insertions and deletions, and copy number alterations associated with autosomal dominant nonsyndromic hearing loss DFNA20/26. All pathogenic findings are confirmed via Sanger sequencing to ensure diagnostic accuracy. In the UAE, this test is essential for accurate molecular diagnosis, genetic counselling, and family planning.
| Feature | Our Test (DFNA20 NGS) | Closest Alternative |
|---|---|---|
| Precision | Full ACTG1 gene sequencing with copy number variant detection | Targeted mutation hot-spot panel only |
| Methodology | Next Generation Sequencing (NGS) + Sanger confirmation | Sanger sequencing alone (lower throughput) |
| Turnaround Time | 21โ28 Business Days (DHA-regulated laboratory) | 5โ6 Weeks (overseas referral) |
Physician Insight & Safety Protocols
โThe ACTG1 genetic test provides critical diagnostic clarity for families with hereditary hearing loss. As a Consultant Medical Genetics, I emphasise that every positive finding must be correlated with comprehensive audiometric assessment and family segregation analysis. This test empowers precise genetic counselling and informs decisions regarding cochlear implantation and auditory rehabilitation. The result is a cornerstone of personalised care, never a standalone diagnosis.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Clinical Advisory
Do not discontinue prescribed medication, hearing aids, or auditory devices without consulting your treating ENT specialist or audiologist. This genetic test does not replace ongoing audiological management or emergency care.
Exclusion Criteria & Emergency Red Flags
- Active systemic infection or severe anaemia (postpone phlebotomy until stabilised).
- Known severe bleeding disorder without medical clearance.
- For minor patients under UAE law, written guardian consent is mandatory in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: Sudden profound hearing loss, acute vertigo, or facial nerve palsy require immediate emergency care โ do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. How accurate is the ACTG1 genetic test for confirming DFNA20 hearing loss?
Our NGS assay achieves greater than 99.9% analytical sensitivity for single nucleotide variants and small insertions or deletions in the ACTG1 gene. All reported pathogenic variants are confirmed by Sanger sequencing, ensuring diagnostic reliability for clinical decision-making.
2. What specialists should interpret my result and plan further care?
An ENT doctor, a clinical geneticist, and an audiologist collaborate to translate your genomic finding into a personalised hearing management plan. This multidisciplinary approach addresses cochlear implant candidacy, auditory rehabilitation, and family counselling comprehensively.
3. Is my genetic data protected under UAE privacy laws?
Absolutely. All genetic information is processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, guaranteeing strict confidentiality and prohibiting unauthorised disclosure.
4. What sample type is required and how should I prepare?
A 4 mL peripheral blood sample in an EDTA tube (lavender top) is required. No fasting is needed; stay well hydrated. Avoid dietary supplements 24 hours before collection and inform the phlebotomist of all medications. A mandatory pre-test genetic counselling session to document family pedigree will be scheduled.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to the highest standards of data protection and clinical governance. All genetic test results are processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and safety protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139), ensuring rigorous quality management across all diagnostic processes.
Clinical & Logistical Metadata
| Test Name | ACTG1 Gene Autosomal Dominant Deafness Type 20 (DFNA20) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21โ28 Business Days |
| Sample Type / Matrix | Peripheral whole blood (4 mL in EDTA tube, lavender top) |
| Methodology Used | Next Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians